NSD3 and carcinoma: To further validate the results from TCGA databases, we collected five pairs of LUAD clinical samples and para‐carcinoma tissues to test the protein levels of NSD3 by Western Blot (Figure 1G) and immunohistochemistry (IHC) (Figure 1H,I), which confirmed that NSD3 was downregulated in LUAD tissue than in peritumoral tissue.